CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) - USD ($)	3 Months Ended		6 Months Ended
	Jan. 31, 2017	Jan. 31, 2016	Jan. 31, 2017	Jan. 31, 2016
Operating Expenses:
Research and development	$ 75,640	$ 67,628	$ 75,640	$ 245,198
General and administrative	140,087	89,904	242,905	1,229,913
Total Operating Expenses	215,727	157,532	318,545	1,475,111
Operating Loss	(215,727)	(157,532)	(318,545)	(1,475,111)
Other Income/(Expense):
Interest expense	(126,669)	(102,187)	(243,508)	(199,910)
Impairment of goodwill	(14,335,822)		(14,335,822)
Change in fair value of derivative liabilities (Note 8)	(1,104,969)	212,329	(325,074)	(103,634)
Net (Loss)			(15,222,949)	(1,778,655)
Net (loss) attributable to noncontrolling interests	(27,283)		(27,283)
Net (Loss) Available to Common Stockholders	$ (15,755,904)	$ (47,390)	$ (15,195,666)	$ (1,778,655)
Net (Loss) Per Common Share - Basic and Diluted	$ (17.16)	$ (0.05)	$ (16.63)	$ (2.07)
Shares Used to Compute (Loss) per Share - basic and diluted	918,416	870,325	913,479	860,226
Other Comprehensive Income
Net (Loss)	$ (15,755,904)	$ (47,390)	$ (15,195,666)	$ (1,778,655)
Change in foreign currency translation adjustments	1,339	(2,152)	8,513	(5,087)
Comprehensive Income (Loss) and Comprehensive Income (Loss) Available to Common Stockholders	$ (15,754,565)	$ (49,542)	$ (15,187,153)	$ (1,783,742)